Document Type
Original Article
Abstract
Background: Triglyceride intake or synthesis increases and/or triglyceride outflow decreases in the liver, respectively, to cause hepatic steatosis. Aim of the Work: To evaluate serum levels of proprotein convertase subtilisin kexin type 9 (pcsk9) as a diagnostic biomarker of hepatic steatosis and their correlations with the severity of the disease. Subject and Methods: This case-control research was conducted in the Department of Internal Medicine, Al-Zahraa University Hospital, and included sixty Egyptian patients with hepatic steatosis (group I) diagnosed by pelvic-abdominal ultrasound with (group Ib includes 30 cases) or without (group Ia includes 30 cases) diabetes mellitus, as well as thirty apparently healthy individuals as a control group (group II). Results: Differences in PCSK9, fasting insulin, and HOMA-IR across study groups are extremely statistically considerable (p-value< 0.001). Differences in cholesterol, HDL, and LDL are extremely statistically considerable (p-value
Keywords
PCSK9, hepatic steatosis, HOMA-IR, LDL, HDL.
Subject Area
Internal Medicine
How to Cite This Article
Antar, Alaa M. E.; Ahmed, Karima Youssef; Diab, Fatma El Zahraa AE; and Kotb, Fatma M.
(2023)
"Evaluation of serum proprotein convertase subtilisin kexin type 9 (PCSK9) as a diagnostic biomarker of hepatic steatosis,"
Al-Azhar International Medical Journal: Vol. 4:
Iss.
10, Article 32.
DOI: https://doi.org/10.58675/2682-339X.2003
